Impact of Cocaine History on Pharmacotherapy Effectiveness
Impact of Cocaine History on Pharmacotherapy Effectiveness
批准号:
10750162
负责人:
Madison M Marcus
金额:
$1.94万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-08-25 至 2024-01-01
关键词:
AnimalsAttenuatedBasic ScienceBehaviorBehavioralCHRM1 geneChoice BehaviorClinicalCocaineCocaine AbuseCocaine DependenceCocaine use disorderComplexDataDevelopmentDopamineDrug usageEffectivenessEnvironmentExperimental DesignsExposure toFemaleFiberFoodFrequenciesHealthHourHumanInfusion proceduresKnowledgeLaboratory AnimalsMeasuresMediatingMethadoneMethodsModelingMonitorMuscarinic Acetylcholine ReceptorNaltrexoneNeurobiologyNucleus AccumbensOpiate AddictionPharmaceutical PreparationsPharmacologyPharmacotherapyPhotometryProceduresPsychological reinforcementPublic HealthPublicationsPublishingRattusRecording of previous eventsResearchRodentSignal TransductionSourceSubstance Use DisorderTechnologyTestingTrainingUnited StatesUnited States Food and Drug Administrationaddictionbehavioral pharmacologybehavioral phenotypingcareer developmentcocaine self-administrationcocaine useepidemiologic dataexperimental studyhuman subjectimprovedinnovationmaleneuralneurochemistrynon-drugnonhuman primateopioid use disorderoverdose deathpositive allosteric modulatorpre-clinicalpre-clinical researchreinforcerresponsereward circuitryscreeningtreatment effect
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
With cocaine-related overdose deaths increasing every year, cocaine abuse is a serious public health concern.
Despite decades of basic research, there are still no Food and Drug-approved pharmacotherapies for cocaine
use disorder (CUD). A growing body of evidence suggests that prior cocaine use history may alter the
development and screening of new CUD pharmacotherapies. We propose to leverage the translational utility of
preclinical drug-vs-nondrug choice procedures to determine how different cocaine self-administration histories
impact the effectiveness of the muscarinic acetylcholine receptor (mAChR)1 positive allosteric modulator
VU0364572 to attenuate cocaine-vs-food choice and cocaine-induced increases in nucleus accumbens (NAc)
dopamine (DA) release using fiber photometry (i.e., dLight). The scientific premise of this project is that
candidate medications that are effective in decreasing drug choice across a broader range of experimental
conditions, including cocaine history, would be hypothesized to be more effective clinically. Aim 1 will
determine the effects of behavioral history (i.e., short- vs extended-access cocaine self-administration) on
VU0364572 effectiveness to attenuate cocaine-vs-food choice behavior. In a 2 x 4 experimental design, each
group will undergo either short-access (ShA) or extended-access (EA) cocaine self-administration conditions.
Under these two access conditions, effects of 4 treatments (vehicle, 0.32, 1.0, and 1.8 mg/kg VU0364572) will
be assessed. Aim 2 will determine the effects of cocaine history on effectiveness of VU0364572 to attenuate
cocaine-elevated NAc DA release using dLight technology. In a 3 x 2 experimental design, each group will be
exposed to one of three cocaine access conditions (ShA, EA, or cocaine naïve) and either vehicle or
VU0364572 treatment. Using dLight fiber photometry, NAc DA response to cocaine infusions will be assessed.
These neurochemical endpoints will be compared across groups and collected in conjunction with cocaine-vs-
food choice data, allowing for within-subjects comparison of neurochemical and behavioral data. Completion of
these studies will test innovative and translationally relevant hypotheses regarding the effects of cocaine
history on mAChR1 PAM efficacy to decrease cocaine self-administration and cocaine-induced enhancement
of mesolimbic DA signaling.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金